Suche Struktur Suche
wx_img
Inquiry Form
  1. Home
  2. Olverembatinib

Olverembatinib

Ascentage Pharma announced that updated results from three studies of olverembatinib, have been released in posters at the 2024 European Hematology Association Hybrid Congress, taking place in Madrid, Spain.
Olverembatinib (HQP1351) is an oral, third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) developed by Ascentage Pharma for the treatment of chronic myeloid leukaemia (CML), acute myeloid leukaemia, acute lymphoblastic leukaemia (ALL) and solid tumours, including gastrointestinal stromal tumours (GIST). Olverembatinib is an ATP binding-site inhibitor of wild type BCR-ABL1 kinase and a broad spectrum of BCR-ABL1 mutants, including mutant T315I, which confers resistance against all first- and second-generation TKIs. 

tert-Butyl 5-bromo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate
tert-Butyl 5-bromo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate
CM151955
1299607-55-8
Methyl 3-ethynyl-4-methylbenzoate
Methyl 3-ethynyl-4-methylbenzoate
CM318788
1255099-13-8
4-((4-Methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)aniline
4-((4-Methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)aniline
CM169811
694499-26-8
methyl 3-iodo-4-methylbenzoate
methyl 3-iodo-4-methylbenzoate
CM101804
90347-66-3
5-bromo-1H-pyrazolo[3,4-b]pyridine
5-bromo-1H-pyrazolo[3,4-b]pyridine
CM103832
875781-17-2
5-ethynyl-1H-pyrazolo[3,4-b]pyridine
5-ethynyl-1H-pyrazolo[3,4-b]pyridine
CM111790
1207351-15-2